卡培他滨联合吉西他滨二线方案治疗晚期转移性乳腺癌临床研究

目的观察卡培他滨联合吉西他滨二线治疗蒽环类和（或）紫杉类耐药的晚期转移性乳腺癌患者的近期疗效及不良反应。方法卡培他滨2000 mg/m2.d,第1~14 d,每天分2次口服。吉西他滨1000 mg/m2,第1、8 d,21天为1周期。最少完成2周期,最多6周期化疗。结果 34例患者中,CR 3例（8.82%）,PR 12例（35.29%）,SD 11例（32.35%）,PD 8例（23.53%）,总有效率（CR＋PR）为44.12%。结论卡培他滨联合吉西他滨二线治疗蒽环类和（或）紫杉类耐药转移性乳腺癌患者疗效较好,不良反应可以耐受。可以作为蒽环类和（或）紫杉类耐药的晚期乳腺癌患者的一个有效解救治疗方案。

Clinical study on capecitabine and gemcitabine as second-line treatment in patients with metastatic breast cancer

Objective To evaluate the efficacy and toxicity of the combination of capecitabine and gemcitabine as second-line treatment of anthracycline and（or） taxol resistant metastatic breast cancer patients.Methods Patients with metastatic breast cancer were treated with capecitabine 2000mg/m2/d orally bid on day 1~14 and gemcitabine 1000 mg/m2 IV on days 1 and 8 and repeated for 21 days.Results Complete remission was 3/34（8.82%） and partial remission was 12/34（35.29%）.Stable disease was 11/34（32.35%） and progressive disease was 8/34（23.53%）.Conclusion Combination of capecitabine and gemcitabine is an active and safe regimen as second-line therapy for anthracycline and（or） taxol resistant metastatic breast cancer.It can be a salvage treatment option for anthracycline and（or） taxo1 resistant metastatic breast cancer patients.